Department of Radiation Oncology, Penn State University Hershey College of Medicine, Hershey, PA.
Department of Radiation Oncology, Penn State University Hershey College of Medicine, Hershey, PA.
Semin Nucl Med. 2019 May;49(3):182-188. doi: 10.1053/j.semnuclmed.2019.01.002. Epub 2019 Feb 14.
Colorectal cancer (CRC) is the fourth most common cancer in the United States. Most patients diagnosed with CRC will eventually develop metastases. The liver is the most common site of metastases from CRC and liver metastases are the most common cause of death for patients with CRC. Selective internal radiotherapy (SIRT) using yttrium 90 microspheres has emerged as a safe and effective treatment modality for controlling hepatic tumor burden in inoperable patients with liver-only or liver-predominant metastatic CRC. This article serves to review the available data on SIRT in the treatment of liver metastases from CRC in the salvage and first-line setting. Recently published phase III randomized data showing a significant improvement in liver progression-free survival from the addition of SIRT to standard chemotherapy in the first-line setting, while demonstrating no significant improvement in overall survival, will be reviewed. In addition, the present article examines the role of SIRT in the management of CRC liver metastases from right-sided colon cancers in which SIRT has been shown to improve overall survival when combined with chemotherapy in the first-line setting and explores appropriate patient selection for future studies.
结直肠癌(CRC)是美国第四大常见癌症。大多数被诊断患有 CRC 的患者最终会发展为转移。肝脏是 CRC 转移的最常见部位,肝脏转移是 CRC 患者死亡的最常见原因。用钇 90 微球进行选择性内放射治疗(SIRT)已成为一种安全有效的治疗方法,可控制无法手术的仅肝脏或肝脏为主的转移性 CRC 患者的肝肿瘤负荷。本文旨在回顾 SIRT 在挽救性和一线治疗中治疗 CRC 肝转移的可用数据。最近发表的 III 期随机数据显示,在一线治疗中添加 SIRT 可显著改善肝脏无进展生存期,而在总生存期方面无显著改善,将对此进行回顾。此外,本文还探讨了 SIRT 在管理右半结肠癌 CRC 肝转移中的作用,SIRT 与化疗联合用于一线治疗时可提高总生存期,并探讨了未来研究中合适的患者选择。